These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27167707)

  • 1. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
    Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
    Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
    Lee A; Kang J; Lee H; Lee YS; Choi YJ; Lee KH; Nistala GJ; Scafe CR; Choi J; Yoo J; Han M D E; Kim Y; Kim M
    Pathol Res Pract; 2019 Nov; 215(11):152595. PubMed ID: 31570282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
    Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
    Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
    Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
    BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    Kowalik A; Zalewski K; Kopczyński J; Siołek M; Lech M; Hińcza K; Kalisz J; Chrapek M; Zięba S; Furmańczyk J; Jedliński M; Chłopek M; Misiek M; Góźdź S
    Pol J Pathol; 2019; 70(2):115-126. PubMed ID: 31556562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC
    Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
    BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
    Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    Kim ET; Jeong HE; Yoon HJ; Kim KH; Suh DS
    Taiwan J Obstet Gynecol; 2023 Jan; 62(1):66-70. PubMed ID: 36720553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
    Hennessy BT; Timms KM; Carey MS; Gutin A; Meyer LA; Flake DD; Abkevich V; Potter J; Pruss D; Glenn P; Li Y; Li J; Gonzalez-Angulo AM; McCune KS; Markman M; Broaddus RR; Lanchbury JS; Lu KH; Mills GB
    J Clin Oncol; 2010 Aug; 28(22):3570-6. PubMed ID: 20606085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
    Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
    Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    Mazzuccato G; De Bonis M; Carboni V; Marchetti C; Urbani A; Scambia G; Capoluongo E; Fagotti A; Minucci A
    Mol Biol Rep; 2020 Jun; 47(6):4897-4903. PubMed ID: 32468256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
    Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.